Terms: = Lung cancer AND ALDH2, ALDHI, 217, ENSG00000111275, ALDH-E2, P05091, MGC1806, ALDM AND Treatment
197 results:
1. Area-based disparities in non-small-cell lung cancer survival.
Paakkola NM; Jekunen A; Sihvo E; Johansson M; Andersén H
Acta Oncol; 2024 Apr; 63():146-153. PubMed ID: 38591350
[TBL] [Abstract] [Full Text] [Related]
2. Clinicopathological, metastatic and prognostic features of stage IV esophageal adenocarcinoma versus squamous cell carcinoma: a SEER database analysis.
Pan L; Zhang Y; Gao Y; Qiu J
Chin Clin Oncol; 2024 Feb; 13(1):2. PubMed ID: 38372056
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy and safety of second-line camrelizumab combined with apatinib and chemotherapy in patients with advanced lung adenocarcinoma: A prospective, open-label, multicentric study.
Yao Y; Wang Y; Du Y; Jiang F; Liang H; Bi M; Xie H; Peng W; Pan Y
Int Immunopharmacol; 2023 Dec; 125(Pt B):111147. PubMed ID: 37956490
[TBL] [Abstract] [Full Text] [Related]
4. The impact of comorbidities on tuberculosis treatment outcomes in Poland: a national cohort study.
Nowiński A; Wesołowski S; Korzeniewska-Koseła M
Front Public Health; 2023; 11():1253615. PubMed ID: 37732096
[TBL] [Abstract] [Full Text] [Related]
5. Individualized Stereotactic Ablative Radiotherapy for lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial.
Gensheimer MF; Gee H; Shirato H; Taguchi H; Snyder JM; Chin AL; Vitzthum LK; Maxim PG; Wakelee HA; Neal J; Das M; Chang DT; Kidd E; Hancock SL; Shultz DB; Horst KC; Le QT; Wong S; Brown E; Nguyen N; Liang R; Loo BW; Diehn M
JAMA Oncol; 2023 Nov; 9(11):1525-1534. PubMed ID: 37707820
[TBL] [Abstract] [Full Text] [Related]
6. Efficacy of paclitaxel-carboplatin with bevacizumab as a late-line therapy for patients with advanced nonsquamous non-small cell lung cancer: A platinum rechallenge.
Sugisaka J; Toi Y; Kawashima Y; Domeki Y; Aiba T; Kawana S; Nakamura A; Yamanda S; Kimura Y; Sugawara S
Thorac Cancer; 2023 Nov; 14(31):3140-3146. PubMed ID: 37699787
[TBL] [Abstract] [Full Text] [Related]
7. [Impacts of LncRNA NORAD on the Proliferation, Apoptosis, and Chemosensitivity of Non-small Cell lung cancer Cells by Regulating ZNF217 through MiR-199a-3p].
Gao Y; Luo X; Liao P; Luo Y
Zhongguo Fei Ai Za Zhi; 2023 Jul; 26(7):479-486. PubMed ID: 37653011
[TBL] [Abstract] [Full Text] [Related]
8. A novel telomere-related gene prognostic signature for survival and drug treatment efficiency prediction in lung adenocarcinoma.
Chen H; Liang W; Zheng W; Li F; Pan X; Lu Y
Aging (Albany NY); 2023 Aug; 15(16):7956-7973. PubMed ID: 37589509
[TBL] [Abstract] [Full Text] [Related]
9. [Effect of Different Antitumor Regimens on Incidence and Severity of Corona Virus
Disease 2019 Pneumonia in lung cancer Patients:
A Single-center Retrospective Study].
Lu W; Lv J; Wang Q; Yao Y; Wang D; Chen J; Wu G; Gu X; Li H; Chen Y; Han H; Lv T; Song Y; Zhan P
Zhongguo Fei Ai Za Zhi; 2023 Jun; 26(6):429-438. PubMed ID: 37488080
[TBL] [Abstract] [Full Text] [Related]
10. Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis.
Soares LR; Vilbert M; Rosa VDL; Oliveira JL; Deus MM; Freitas-Junior R
ESMO Open; 2023 Aug; 8(4):101613. PubMed ID: 37481956
[TBL] [Abstract] [Full Text] [Related]
11. Expression Pattern and Prognostic Analysis of Branched-Chain Amino Acid Catabolism-Related Genes in Non-Small Cell lung cancer.
Yao X; Deng Y; Zhou J; Jiang L; Song Y
Front Biosci (Landmark Ed); 2023 Jun; 28(6):107. PubMed ID: 37395022
[TBL] [Abstract] [Full Text] [Related]
12. Dissecting the alternation landscape of mitochondrial metabolism-related genes in lung adenocarcinoma and their latent mechanisms.
Jin X; Liu D; Kong D; Zhou X; Zheng L; Xu C
Aging (Albany NY); 2023 Jun; 15(12):5482-5496. PubMed ID: 37335087
[TBL] [Abstract] [Full Text] [Related]
13. Stereotactic ablative radiotherapy before resection to avoid delay for early-stage lung cancer or oligometastases during the COVID-19 pandemic: Pathologic outcomes from the SABR-BRIDGE protocol.
Kidane B; Gerard IJ; Spicer J; Kim JO; Fiset PO; Wawryko P; Cecchini MJ; Inculet R; Abdulkarim B; Fortin D; Qiabi M; Qing G; Enns S; Bashir B; Tankel J; Wakeam E; Warner A; Kopek N; Yaremko BP; Rodrigues GB; Laba JM; Qu M; Malthaner RA; Palma DA
Cancer; 2023 Sep; 129(18):2798-2807. PubMed ID: 37221679
[TBL] [Abstract] [Full Text] [Related]
14. Systemic inflammation influences the prognosis of patients with radically resected non-small cell lung cancer and correlates with the immunosuppressive microenvironment.
Wang P; Wang S; Sun Z; Li H; Zhao Y; Li Y; Yang F; Wang J; Chen K; Qiu M; Li X
Int J Cancer; 2023 Aug; 153(4):826-842. PubMed ID: 37186387
[TBL] [Abstract] [Full Text] [Related]
15. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
Lu S; Wu L; Jian H; Cheng Y; Wang Q; Fang J; Wang Z; Hu Y; Han L; Sun M; Miao L; Ding C; Cui J; Wang K; Li B; Li X; Ye F; Liu A; Pan Y; Cang S; Zhou H; Sun X; Shen Y; Wang S; Zhang W; He Y
Lancet Respir Med; 2023 Jul; 11(7):624-636. PubMed ID: 37156249
[TBL] [Abstract] [Full Text] [Related]
16. FTO-stabilized miR-139-5p targets ZNF217 to suppress prostate cancer cell malignancies by inactivating the PI3K/Akt/mTOR signal pathway.
Azhati B; Reheman A; Dilixiati D; Rexiati M
Arch Biochem Biophys; 2023 Jun; 741():109604. PubMed ID: 37080415
[TBL] [Abstract] [Full Text] [Related]
17. Incidence of gastrointestinal malignancies increases in persons received eradication therapy for Helicobacter pylori: A cohort study.
Kosunen TU; Nieminen AA; Kokkola A; Arkkila P; Pukkala E; Rautelin H
Helicobacter; 2023 Jun; 28(3):e12979. PubMed ID: 37009972
[TBL] [Abstract] [Full Text] [Related]
18. Efficacy, Safety, and Health-Related Quality of Life With Camrelizumab Plus Pemetrexed and Carboplatin as First-Line treatment for Advanced Nonsquamous NSCLC With Brain Metastases (CAP-BRAIN): A Multicenter, Open-Label, Single-Arm, Phase 2 Study.
Hou X; Zhou C; Wu G; Lin W; Xie Z; Zhang H; Yi J; Peng Z; Yin L; Ma C; Chen L
J Thorac Oncol; 2023 Jun; 18(6):769-779. PubMed ID: 36738928
[TBL] [Abstract] [Full Text] [Related]
19. Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study.
Yagi K; Maruo A; Ishida S; Aizawa F; Ushio S; Sakaguchi S; Kajizono M; Niimura T; Goda M; Hamano H; Izawa-Ishizawa Y; Zamami Y; Ishizawa K
Clin Exp Med; 2023 Oct; 23(6):2799-2804. PubMed ID: 36738305
[TBL] [Abstract] [Full Text] [Related]
20. Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis.
Zhu Y; Liu K; Qin Q; Zhu H
Front Immunol; 2022; 13():1044678. PubMed ID: 36685541
[TBL] [Abstract] [Full Text] [Related]
[Next]
